Clinical Trials Sponsored by Ansun Biopharma, Inc.

Total 331 results

Ansun Biopharma, Inc.

Withdrawn

DAS181 for STOP COVID-19

COVID-19

Italy
Ansun Biopharma, Inc.

Unknown

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) (STOP-Flu)

Influenza Infection | SAD-RV Infection and COVID-19

China
Ansun Biopharma, Inc.

Completed

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection (PIV)

Parainfluenza

United States
Ansun Biopharma, Inc.

Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

COVID-19 | Lower Respiratory Tract Infection | Immunocompromised | Parainfluenza

United States, Australia, China, Denmark, France, Hong Kong, Korea, Republic of, Taiwan
Ansun Biopharma, Inc.

Completed

Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

Influenza

United States
Ansun Biopharma, Inc.

Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

Parainfluenza

United States
Renmin Hospital of Wuhan University
Ansun Biopharma, Inc.

Completed

DAS181 for Severe COVID-19: Compassionate Use

COVID-19

China
Ansun Biopharma, Inc.
National Institutes of Health (NIH)

Completed

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

Influenza

United States
Ansun Biopharma, Inc.
National Institutes of Health (NIH)

Completed

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis (DAS181)

Bronchiectasis | Asthma

United States
Ansun Biopharma, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

DAS181 Single Dose Escalation Study in Healthy Adults

Healthy

United States
Ansun Biopharma, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Single Dose Escalating Study of DAS181 in Adults

Influenza

United States
BioPharmX, Inc.

Completed

Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel

Acne Vulgaris

United States
BioPharmX, Inc.

Unknown

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea (PRISM)

Papulopustular Rosacea

United States
BioPharmX, Inc.

Completed

Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline

Acne

United States
BioPharmX, Inc.

Completed

A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness

Fibrocystic Breast Condition (FBC)

United States, Canada
BioPharmX, Inc.

Completed

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

Acne Vulgaris

United States
BioPharmX, Inc.

Completed

Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

Moderate to Severe Papulopustular Rosacea

United States
BioPharmX, Inc.

Completed

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris (OPAL)

Acne Vulgaris

United States
HC Biopharma Inc.

Recruiting

A Study of HC006 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
AiViva BioPharma, Inc.

Recruiting

Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

United States
Vitro Biopharma Inc.

Not yet recruiting

Safety & Efficacy of AlloRx SC® in PTHS Patients

Pitt Hopkins Syndrome
Acrotech Biopharma Inc.

Active, not recruiting

A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Aytu BioPharma, Inc.

Withdrawn

A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0

Male Infertility

United States
Nitto BioPharma, Inc.

Active, not recruiting

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer

United States
AiViva BioPharma, Inc.

Completed

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

Keloid

United States
Staidson Biopharma Inc.

Completed

The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects

Healthy

United States
AiViva BioPharma, Inc.

Completed

A Safety and Efficacy Study to Evaluate Wound Healing

Wound Heal

United States
Acrotech Biopharma Inc.

Withdrawn

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

Non Hodgkin's Lymphoma
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma

United States
Acrotech Biopharma Inc.

Completed

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

United Kingdom, United States
Acrotech Biopharma Inc.

Completed

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Mycosis Fungoides | Sezary Syndrome | Cutaneous T-cell Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma

United States, Italy
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Carcinoma, Transitional Cell | Bladder Cancer | Bladder Neoplasm

Spain, France, Belgium, United States, Argentina, Croatia
Acrotech Biopharma Inc.

Completed

Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States
Alios Biopharma Inc.

Completed

First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Chronic Hepatitis C

France, Moldova, Republic of, Georgia
Alios Biopharma Inc.

Completed

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Hepatitis B

New Zealand
Therapure Biopharma Inc

Unknown

Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Micelle BioPharma Inc

Unknown

A Sickle CEll Disease ComplicatioN Trial (ASCENT)

Sickle Cell Disease
Oncolys BioPharma Inc

Unknown

A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer

Esophageal Cancer

Japan
Alios Biopharma Inc.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers

Healthy

United Kingdom
Alios Biopharma Inc.

Terminated

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Hepatitis B | Chronic Hepatitis B | Viral Hepatitis B

New Zealand
Alios Biopharma Inc.

Completed

A Study to Assess the PK of AL-794 Formulations in Healthy Subjects

Influenza

United Kingdom
ReveraGen BioPharma, Inc.

Completed

A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

Healthy

United States
Galena Biopharma, Inc.

Completed

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)

Breast Cancer With Low to Intermediate HER2 Expression

United States, United Kingdom, France, Israel, Germany, Canada, Russian Federation, Romania, Bulgaria, Czech Republic, Hungary, Poland, Ukraine
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
Fountain Biopharma Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers

Healthy
CeNeRx BioPharma Inc.

Completed

Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression (CX157-201)

Treatment Resistant Depression

United States
CeNeRx BioPharma Inc.

Completed

A Study of CX157 (TriRima) for the Treatment of Depression (CX157-200)

Major Depressive Disorder

United States
CeNeRx BioPharma Inc.

Unknown

Pharmacokinetic Study of CXB909 in Healthy Male Subjects

Healthy
ARCA Biopharma, Inc.

Unknown

Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery (SNAP-CABG-OFF)

Heart Disease
ARCA Biopharma, Inc.

Terminated

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

Arterial Occlusive Diseases

United States

3

Subscribe